Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 15.1
edited by manuelmenendez
on 2025/01/27 23:58
Change comment: There is no comment for this version
To version 7.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -15,7 +15,7 @@
15 15  (((
16 16  = What is this about and what can I find here? =
17 17  
18 -== **Overview** ==
18 +==== **Overview** ====
19 19  
20 20  The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 21  
... ... @@ -23,9 +23,6 @@
23 23  * **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24 24  * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 25  
26 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 -
28 -
29 29  This methodology enables:
30 30  
31 31  * Greater precision in diagnosis.
... ... @@ -32,7 +32,7 @@
32 32  * Integration of incomplete datasets using AI-driven probabilistic modeling.
33 33  * Stratification of patients for personalized treatment.
34 34  
35 -== **Diagnostic Axes** ==
32 +==== **Diagnostic Axes** ====
36 36  
37 37  * (((
38 38  **Axis 1: Etiology**
... ... @@ -56,11 +56,28 @@
56 56  * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
57 57  )))
58 58  
59 -== **Applications** ==
56 +==== **Case Studies** ====
60 60  
58 +1. (((
59 +**Sporadic Alzheimer’s Disease**:
60 +
61 +* Axis 1: Sporadic (ApoE4, poor sleep habits).
62 +* Axis 2: Amyloid-beta plaques, elevated NFL.
63 +* Axis 3: Right hippocampus atrophy (visual memory loss).
64 +)))
65 +1. (((
66 +**Genetic Parkinson’s Disease**:
67 +
68 +* Axis 1: Genetic (LRRK2 mutation).
69 +* Axis 2: Alpha-synuclein aggregation.
70 +* Axis 3: Substantia nigra degeneration (motor dysfunction).
71 +)))
72 +
73 +==== **Applications** ====
74 +
61 61  This system enhances:
62 62  
63 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
77 +* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
64 64  * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
65 65  
66 66  == Who has access? ==
... ... @@ -67,13 +67,13 @@
67 67  
68 68  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
69 69  
70 -== How to Contribute ==
84 +== How to Contribute: ==
71 71  
72 72  * Access the `/docs` folder for guidelines.
73 73  * Use `/code` for the latest AI pipelines.
74 74  * Share feedback and ideas in the wiki discussion pages.
75 75  
76 -== Key Objectives ==
90 +== Key Objectives: ==
77 77  
78 78  * Develop interpretable AI models for diagnosis and progression tracking.
79 79  * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
... ... @@ -87,7 +87,7 @@
87 87  {{toc/}}
88 88  {{/box}}
89 89  
90 -== Main contents ==
104 +== Main contents: ==
91 91  
92 92  * `/docs`: Documentation and contribution guidelines.
93 93  * `/code`: Machine learning pipelines and scripts.
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view